Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination
- Autores
- Castro, Eliana Florencia; Acosta, Julián; Moriena, Lucía; Rios Medrano, Mayra; Cibello, Malena Tejerina; Codino, Eduardo; Taborda, Miguel Ángel; Álvarez, Diego E.; Cavatorta, Ana
- Año de publicación
- 2023
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels.
Instituto de Virología
Fil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina
Fil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); Argentina
Fil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin
Fil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; Argentina
Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; Argentina
Fil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina
Fil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; Argentina
Fil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina
Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; Argentina - Fuente
- mSphere 8 (3) : e0066222 (June 2023)
- Materia
-
Severe Acute Respiratory Syndrome Coronavirus 2
Humoral Immunity
Immune Response
Vaccination
Coronavirus del Síndrome Respiratorio Agudo Grave 2
Inmunidad Humoral
Respuesta Inmunológica
Vacunación
Argentina
Sputnik V - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- http://creativecommons.org/licenses/by-nc-sa/4.0/
- Repositorio
- Institución
- Instituto Nacional de Tecnología Agropecuaria
- OAI Identificador
- oai:localhost:20.500.12123/16603
Ver los metadatos del registro completo
id |
INTADig_2bb9b6e9ae986422269623907296f162 |
---|---|
oai_identifier_str |
oai:localhost:20.500.12123/16603 |
network_acronym_str |
INTADig |
repository_id_str |
l |
network_name_str |
INTA Digital (INTA) |
spelling |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccinationCastro, Eliana FlorenciaAcosta, JuliánMoriena, LucíaRios Medrano, MayraCibello, Malena TejerinaCodino, EduardoTaborda, Miguel ÁngelÁlvarez, Diego E.Cavatorta, AnaSevere Acute Respiratory Syndrome Coronavirus 2Humoral ImmunityImmune ResponseVaccinationCoronavirus del Síndrome Respiratorio Agudo Grave 2Inmunidad HumoralRespuesta InmunológicaVacunaciónArgentinaSputnik VSARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels.Instituto de VirologíaFil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; ArgentinaFil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); ArgentinaFil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinFil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; ArgentinaFil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; ArgentinaFil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; ArgentinaFil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; ArgentinaFil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; ArgentinaFil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; ArgentinaAmerican Society for Microbiology2024-02-14T16:56:51Z2024-02-14T16:56:51Z2023-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://hdl.handle.net/20.500.12123/16603https://journals.asm.org/doi/10.1128/msphere.00662-222379-5042https://doi.org/10.1128/msphere.00662-22mSphere 8 (3) : e0066222 (June 2023)reponame:INTA Digital (INTA)instname:Instituto Nacional de Tecnología Agropecuariaenginfo:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by-nc-sa/4.0/Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)2025-10-16T09:31:27Zoai:localhost:20.500.12123/16603instacron:INTAInstitucionalhttp://repositorio.inta.gob.ar/Organismo científico-tecnológicoNo correspondehttp://repositorio.inta.gob.ar/oai/requesttripaldi.nicolas@inta.gob.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:l2025-10-16 09:31:28.191INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuariafalse |
dc.title.none.fl_str_mv |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
title |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
spellingShingle |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination Castro, Eliana Florencia Severe Acute Respiratory Syndrome Coronavirus 2 Humoral Immunity Immune Response Vaccination Coronavirus del Síndrome Respiratorio Agudo Grave 2 Inmunidad Humoral Respuesta Inmunológica Vacunación Argentina Sputnik V |
title_short |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
title_full |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
title_fullStr |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
title_full_unstemmed |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
title_sort |
Longitudinal follow-up of the immunity to SARS-CoV-2 in health care workers in Argentina : persistence of humoral response and neutralizing capacity after Sputnik V vaccination |
dc.creator.none.fl_str_mv |
Castro, Eliana Florencia Acosta, Julián Moriena, Lucía Rios Medrano, Mayra Cibello, Malena Tejerina Codino, Eduardo Taborda, Miguel Ángel Álvarez, Diego E. Cavatorta, Ana |
author |
Castro, Eliana Florencia |
author_facet |
Castro, Eliana Florencia Acosta, Julián Moriena, Lucía Rios Medrano, Mayra Cibello, Malena Tejerina Codino, Eduardo Taborda, Miguel Ángel Álvarez, Diego E. Cavatorta, Ana |
author_role |
author |
author2 |
Acosta, Julián Moriena, Lucía Rios Medrano, Mayra Cibello, Malena Tejerina Codino, Eduardo Taborda, Miguel Ángel Álvarez, Diego E. Cavatorta, Ana |
author2_role |
author author author author author author author author |
dc.subject.none.fl_str_mv |
Severe Acute Respiratory Syndrome Coronavirus 2 Humoral Immunity Immune Response Vaccination Coronavirus del Síndrome Respiratorio Agudo Grave 2 Inmunidad Humoral Respuesta Inmunológica Vacunación Argentina Sputnik V |
topic |
Severe Acute Respiratory Syndrome Coronavirus 2 Humoral Immunity Immune Response Vaccination Coronavirus del Síndrome Respiratorio Agudo Grave 2 Inmunidad Humoral Respuesta Inmunológica Vacunación Argentina Sputnik V |
dc.description.none.fl_txt_mv |
SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels. Instituto de Virología Fil: Castro, Eliana Florencia. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Castro, Eliana Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Castro, Eliana Florencia. Instituto Nacional de Tecnología Agropecuaria (INTA). Instituto de Virología e Innovaciones Tecnológicas; Argentina Fil: Acosta, Julián. Instituto de Biología Molecular y Celular de Rosario; Argentina Fil: Acosta, Julián. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Acosta, Julián. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Moriena, Lucía. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública (CTSP); Argentina Fil: Rios Medrano, Mayra. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Rios Medrano, Mayra. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentin Fil: Cibello, Malena Tejerina. Universidad Nacional de San Martín. Escuela de Bio y Nanotecnologías; Argentina Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Codino, Eduardo. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología en Salud Pública; Argentina Fil: Taborda, Miguel Ángel. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Álvarez, Diego E. Universidad Nacional de San Martín. Instituto de Investigaciones Biotecnológicas; Argentina Fil: Álvarez, Diego E. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cavatorta, Ana. Instituto de Biología Molecular y Celular de Rosario; Argentina Fil: Cavatorta, Ana. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas; Argentina Fil: Cavatorta, Ana. Universidad Nacional de Rosario. Facultad de Ciencias Bioquímicas y Farmacéuticas. Centro de Tecnología En Salud Pública; Argentina |
description |
SARS-CoV-2 vaccine protection has encountered waning of immune response and breakthrough infections. The hybrid immune response generated by the combination of vaccination and infection was shown to offer higher and broader protection. Here, we present a seroprevalence study of anti-SARS-CoV-2 spike/RBD IgG in 1,121 health care workers immunized with Sputnik V and a follow-up of humoral response at 2 and 24 weeks postvaccination (wpv), including neutralizing antibody response (NAT) against ancestral, Gamma, and Delta variants. The first seroprevalence study showed that among 122 individuals with one dose, 90.2% were seropositive versus 99.7% seropositivity among volunteers with the complete two-dose regimen. At 24 wpv, 98.7% of the volunteers remained seropositive, although antibody levels decreased. IgG levels and NAT were higher in individuals that had acquired COVID-19 previous to vaccination than in naive individuals at 2 and 24 wpv. Antibody levels dropped over time in both groups. In contrast, IgG levels and NAT increased after vaccine breakthrough infection. At 2 wpv, 35/40 naive individuals had detectable NAT against SARS-CoV-2 Gamma and 6/40 against Delta. In turn, 8/9 previously infected individuals developed a neutralizing response against SARS-CoV-2 Gamma and 4/9 against Delta variants. NAT against variants followed a trajectory similar to NAT against ancestral SARS-CoV-2, and breakthrough infection led to an increase in NAT and complete seroconversion against variants. In conclusion, Sputnik V-induced humoral response persisted at 6 months postvaccination, and hybrid immunity induced higher levels of anti-S/RBD antibodies and NAT in previously exposed individuals, boosted the response after vaccination, and conferred wider breadth of protection. IMPORTANCE Since December 2020, Argentina has begun a mass vaccination program. The first vaccine available in our country was Sputnik V, which has been approved for use in 71 countries with a total population of 4 billion people. Despite all the available information, there are fewer published studies on the response induced by Sputnik V vaccination compared to that of other vaccines. Although the global political context has paralyzed the verification by the WHO of the efficacy of this vaccine, our work aims to add new clear and necessary evidence to Sputnik V performance. Our results contribute to general knowledge of the humoral immune response developed by vaccines based on viral vector technology, highlighting the higher immune protection conferred by hybrid immunity and reinforcing the importance of completing vaccination schedules and booster doses to maintain adequate antibody levels. |
publishDate |
2023 |
dc.date.none.fl_str_mv |
2023-06 2024-02-14T16:56:51Z 2024-02-14T16:56:51Z |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/20.500.12123/16603 https://journals.asm.org/doi/10.1128/msphere.00662-22 2379-5042 https://doi.org/10.1128/msphere.00662-22 |
url |
http://hdl.handle.net/20.500.12123/16603 https://journals.asm.org/doi/10.1128/msphere.00662-22 https://doi.org/10.1128/msphere.00662-22 |
identifier_str_mv |
2379-5042 |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-sa/4.0/ Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
American Society for Microbiology |
publisher.none.fl_str_mv |
American Society for Microbiology |
dc.source.none.fl_str_mv |
mSphere 8 (3) : e0066222 (June 2023) reponame:INTA Digital (INTA) instname:Instituto Nacional de Tecnología Agropecuaria |
reponame_str |
INTA Digital (INTA) |
collection |
INTA Digital (INTA) |
instname_str |
Instituto Nacional de Tecnología Agropecuaria |
repository.name.fl_str_mv |
INTA Digital (INTA) - Instituto Nacional de Tecnología Agropecuaria |
repository.mail.fl_str_mv |
tripaldi.nicolas@inta.gob.ar |
_version_ |
1846143567742894080 |
score |
12.712165 |